Tolls and beyond - Many roads to vaccine immunity

New England Journal of Medicine

Volumn 356, Issue 17, 2007, Pages 1776-1778

  Pulendran, Bali ^a  

^a EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM POTASSIUM SULFATE; FREUND ADJUVANT; HEPATITIS B VACCINE; IMMUNOLOGICAL ADJUVANT; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINYLALANYL DIPALMITOYLPHOSPHATIDYLETHANOLAMINE; RIBI ADJUVANT; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 9; UNCLASSIFIED DRUG;

ANTIBODY RESPONSE; ARTICLE; DRUG MECHANISM; HEPATITIS B; HUMAN; IMMUNE RESPONSE; INNATE IMMUNITY; NONHUMAN; PRIORITY JOURNAL; PUBLIC HEALTH; VACCINATION;

EID: 34247470249     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMcibr070454     Document Type: Article

References (3)

1. Gavin AL, Hoebe K, Duong B, et al. Adjuvant-enhanced antibody responses in the absence of toll-like receptor signaling. Science 2006;314:1936-8.
2. Querec T, Bennouna S, Alkan S, et al. Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8, and 9 to stimulate polyvalent immunity. J Exp Med 2006;203:413-24.
3. Krieg AM. Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov 2006;5:471-84.